Observational studyBMJ (Clinical research ed.)2018
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study.
Observational study in BMJ (Clinical research ed.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 482 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
482 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Hepatoprotective effects of oyster-derived bioactive compounds in alcoholic liver disease: a systematic review.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Pooled it
- Psychosocial therapy improves outcomes for alcohol use disorder in people with chronic liver disease: A systematic review and meta-analysis.Hepatology communications · 2025Pooled it
- Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis.Hepatology communications · 2024Pooled it
- Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis.Alimentary pharmacology & therapeutics · 2024Pooled it
- Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2024Pooled it
- Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2023Pooled it
- A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance.Hepatology communications · 2024Trial
- CAREGIVER Randomized Trial of Two Mindfulness Methods to Improve the Burden and Distress of Caring for Persons with Cirrhosis.Digestive diseases and sciences · 2023Trial
- Safety and efficacy of precision hepatectomy in the treatment of primary liver cancer.BMC surgery · 2023Trial
- Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease.Clinical and molecular hepatology · 2026Review
- Genetic and genomic insights across the steatotic liver disease spectrum.Clinical and molecular hepatology · 2026Review
- The INTEGRATE prospective cohort study: Design and methods to evaluate biopsychosocial determinants of outcomes in early liver transplantation for alcohol-associated liver disease.Hepatology communications · 2026Observational
- Article
- Where the final day is spent: patterns in place of death among U.S. adults with alcoholic liver cirrhosis, 1999-2023.Annals of medicine and surgery (2012) · 2026Article
- Comment on: A cross-sectional analysis of liver disease-hypertension comorbid mortality trends in the United States, 1999-2023.Annals of medicine and surgery (2012) · 2026Article
- Social and Functional Risk Patterns and All-Cause Mortality Among US Adults with Chronic Liver Disease.Medical sciences (Basel, Switzerland) · 2026Article
- SIRPα Cleavage Is Associated with Inflammatory Response, Corticosteroid Nonresponse, and Worse Prognosis in Clinical and Preclinical Models of Alcohol-Associated Hepatitis.The American journal of pathology · 2026Article
- Prognostic significance of modified albumin-bilirubin (MALBI) score in cirrhosis patients: A retrospective, single-center experience.Irish journal of medical science · 2026Article
- High incidence of advanced liver disease and mortality in patients presenting with alcohol use disorder.Hepatology communications · 2026Article
- Temporal Trends and Demographic Disparities in Respiratory Failure Mortality Among Adults with Chronic Liver Disease: A National Mortality Database Analysis, 1999 to 2024.Diseases (Basel, Switzerland) · 2026Article
422 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveTo describe liver disease related mortality in the United States during 1999-2016 by age group, sex, race, cause of liver disease, and geographic region.
designObservational cohort study.
settingDeath certificate data from the Vital Statistics Cooperative, and population data from the US Census Bureau compiled by the Center for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (1999-2016).
participantsUS residents.
main outcome measureDeaths from cirrhosis and hepatocellular carcinoma, with trends evaluated using joinpoint regression.
resultsFrom 1999 to 2016 in the US annual deaths from cirrhosis increased by 65%, to 34 174, while annual deaths from hepatocellular carcinoma doubled to 11 073. Only one subgroup-Asians and Pacific Islanders-experienced an improvement in mortality from hepatocellular carcinoma: the death rate decreased by 2.7% (95% confidence interval 2.2% to 3.3%, P<0.001) per year. Annual increases in cirrhosis related mortality were most pronounced for Native Americans (designated as "American Indians" in the census database) (4.0%, 2.2% to 5.7%, P=0.002). The age adjusted death rate due to hepatocellular carcinoma increased annually by 2.1% (1.9% to 2.3%, P<0.001); deaths due to cirrhosis began increasing in 2009 through 2016 by 3.4% (3.1% to 3.8%, P<0.001). During 2009-16 people aged 25-34 years experienced the highest average annual increase in cirrhosis related mortality (10.5%, 8.9% to 12.2%, P<0.001), driven entirely by alcohol related liver disease. During this period, mortality due to peritonitis and sepsis in the setting of cirrhosis increased substantially, with respective annual increases of 6.1% (3.9% to 8.2%) and 7.1% (6.1% to 8.4%). Only one state, Maryland, showed improvements in mortality (-1.2%, -1.7% to -0.7% per year), while many, concentrated in the south and west, observed disproportionate annual increases: Kentucky 6.8% (5.1% to 8.5%), New Mexico 6.0% (4.1% to 7.9%), Arkansas 5.7% (3.9% to 7.6%), Indiana 5.0% (3.8% to 6.1%), and Alabama 5.0% (3.2% to 6.8%). No state showed improvements in hepatocellular carcinoma related mortality, while Arizona (5.1%, 3.7% to 6.5%) and Kansas (4.3%, 2.8% to 5.8%) experienced the most severe annual increases.
conclusionsMortality due to cirrhosis has been increasing in the US since 2009. Driven by deaths due to alcoholic cirrhosis, people aged 25-34 have experienced the greatest relative increase in mortality. White Americans, Native Americans, and Hispanic Americans experienced the greatest increase in deaths from cirrhosis. Mortality due to cirrhosis is improving in Maryland but worst in Kentucky, New Mexico, and Arkansas. The rapid increase in death rates among young people due to alcohol highlight new challenges for optimal care of patients with preventable liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.